Evidence map›Paper›PMID 31812369›Full record

ArticleThe Lancet. Global health2020

Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.

Marc Arbyn, Elisabete Weiderpass, Laia Bruni, Silvia de Sanjosé, Mona Saraiya, Jacques Ferlay, Freddie Bray

Erratum issued 6 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in The Lancet. Global health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 6 registered trials, which are not on this map. Cited by 2,088 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2,088citing papers in PubMed, 10 pooled it
290.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05437692 phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

A Prospective, Single Arm, Phase II Clinical Study on the Treatment of Locally Advanced Cervical Cancer (Ⅱ B to Ⅳ a) With Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy

TypeinterventionalSponsorShanghai Zhongshan HospitalRan2022 to 2025Enrolled19ConditionsLocally Advanced Cervical CancerArmszimberelimab combined With concurrent radiotherapy and chemotherapy
NCT05806125 unknown statusnot on this mapstarted 2023, after this paper: background citation

Clinical Value of the Fertility-preserving Surgery in Cervical Cancer -- the Feasibility of the 'Cuff-sleeve' Suture Method in the Ascending Branch of Uterine Artery Preserved Radical Trachelectomy

TypeobservationalSponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRan2023 to 2024Enrolled100ConditionsCervical Cancer
NCT05904977 unknown statusnot on this map

Preliminary Study on the Metastatic Rate and Clinical Significance of the Anterior Leaf of Vesicouterine Ligament in Early Stage Cervical Cancer

Typeobservational_patient_registrySponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRan2019 to 2024Enrolled460ConditionsCervical CancerArmsType B resection or type C resection of the anterior leaf of vesicouterine ligament during the radical hysterectomy (type C)
NCT06431724 unknown statusnot on this mapstarted 2023, after this paper: background citation

A Prospective Analysis of Adherence to National Cervical Cancer Screening Recommendations in Women Age >65

TypeobservationalSponsorSarasota Memorial Health Care SystemRan2023 to 2024Enrolled300ConditionsCervical CancerArmsPatient Survey, Provider Survey
NCT07259616 completednot on this map

Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities

TypeobservationalSponsorGynaecologisch Oncologisch Centrum ZuidRan2017 to 2023Enrolled46,079ConditionsCervical Intraepithelial Neoplasia, Cervix Uteri Cancer, Human Papilloma Virus, Cervix Carcinoma
NCT07451340 completednot on this mapstarted 2026, after this paper: background citation

Cross-Cultural Adaptation and Psychometric Validation of the Cervical Cancer Screening Uptake Questionnaire (CCSTQ) in Turkish Women

TypeobservationalSponsorAnkara UniversityRan2026 to 2026Enrolled530ConditionsHealthy, Cervical Cancer ScreeningArmsValidity and reliability study
3 · Its place in the literature

Who cites it

2,088 citing papers in PubMed, 10 syntheses or guidelines pooled it, 4,001 citations in OpenAlex.

  1. Pooled it
  2. PET-CT radiomics and artificial intelligence for predicting lymph node metastasis in cervical cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  3. Cervical cancer screening strategies in women 65 years and older in the human papillomavirus era: A systematic review and meta-analysis of human papillomavirus-based testing and self-sampling approaches.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2,028 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Marc ArbynUnit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium. Electronic address: marc.arbyn@sciensano.be.
Elisabete WeiderpassInternational Agency for Research on Cancer, Lyon, France.
Laia BruniConsortium for Biomedical Research in Epidemiology and Public Health, Barcelona, Spain; Unit of Infections and Cancer, Catalonian Institute of Oncology, Barcelona, Spain.
Silvia de SanjoséPATH, Seattle, WA, USA.
Mona SaraiyaCenters for Disease Control and Prevention, Division of Cancer Prevention and Control, Atlanta, GA, USA.
Jacques FerlayInternational Agency for Research on Cancer, Lyon, France.
Freddie BrayInternational Agency for Research on Cancer, Lyon, France.
Centre International de Recherche sur le Cancer · FRCenters for Disease Control and Prevention · USCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESProgram for Appropriate Technology in Health · USSciensano (Belgium) · BE

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundThe knowledge that persistent human papillomavirus (HPV) infection is the main cause of cervical cancer has resulted in the development of prophylactic vaccines to prevent HPV infection and HPV assays that detect nucleic acids of the virus. WHO has launched a Global Initiative to scale up preventive, screening, and treatment interventions to eliminate cervical cancer as a public health problem during the 21st century. Therefore, our study aimed to assess the existing burden of cervical cancer as a baseline from which to assess the effect of this initiative.

methodsFor this worldwide analysis, we used data of cancer estimates from 185 countries from the Global Cancer Observatory 2018 database. We used a hierarchy of methods dependent on the availability and quality of the source information from population-based cancer registries to estimate incidence of cervical cancer. For estimation of cervical cancer mortality, we used the WHO mortality database. Countries were grouped in 21 subcontinents and were also categorised as high-resource or lower-resource countries, on the basis of their Human Development Index. We calculated the number of cervical cancer cases and deaths in a given country, directly age-standardised incidence and mortality rate of cervical cancer, indirectly standardised incidence ratio and mortality ratio, cumulative incidence and mortality rate, and average age at diagnosis.

findingsApproximately 570 000 cases of cervical cancer and 311 000 deaths from the disease occurred in 2018. Cervical cancer was the fourth most common cancer in women, ranking after breast cancer (2·1 million cases), colorectal cancer (0·8 million) and lung cancer (0·7 million). The estimated age-standardised incidence of cervical cancer was 13·1 per 100 000 women globally and varied widely among countries, with rates ranging from less than 2 to 75 per 100 000 women. Cervical cancer was the leading cause of cancer-related death in women in eastern, western, middle, and southern Africa. The highest incidence was estimated in Eswatini, with approximately 6·5% of women developing cervical cancer before age 75 years. China and India together contributed more than a third of the global cervical burden, with 106 000 cases in China and 97 000 cases in India, and 48 000 deaths in China and 60 000 deaths in India. Globally, the average age at diagnosis of cervical cancer was 53 years, ranging from 44 years (Vanuatu) to 68 years (Singapore). The global average age at death from cervical cancer was 59 years, ranging from 45 years (Vanuatu) to 76 years (Martinique). Cervical cancer ranked in the top three cancers affecting women younger than 45 years in 146 (79%) of 185 countries assessed.

interpretationCervical cancer continues to be a major public health problem affecting middle-aged women, particularly in less-resourced countries. The global scale-up of HPV vaccination and HPV-based screening-including self-sampling-has potential to make cervical cancer a rare disease in the decades to come. Our study could help shape and monitor the initiative to eliminate cervical cancer as a major public health problem.

fundingBelgian Foundation Against Cancer, DG Research and Innovation of the European Commission, and The Bill & Melinda Gates Foundation.

Indexed as

Cause of DeathMortalityAdultAgedAged, 80 and overFemaleGlobal Burden of DiseaseHumansIncidenceMiddle AgedUterine Cervical Neoplasms

Identifiers

PMID31812369
PMCPMC7025157
OpenAlexW2993250673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.